Published in Polim Med on January 01, 1977
Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc Chem Res (2009) 2.32
HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev (2009) 2.13
Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Deliv Rev (2012) 1.28
Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction. Biomacromolecules (2010) 1.08
Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm (2006) 1.03
Design, synthesis, and biological evaluation of a robust, biodegradable dendrimer. Bioconjug Chem (2010) 1.00
HYDROGELS FROM SOFT CONTACT LENSES AND IMPLANTS TO SELF-ASSEMBLED NANOMATERIALS. J Polym Sci A Polym Chem (2009) 0.99
Endocytic uptake of a large array of HPMA copolymers: Elucidation into the dependence on the physicochemical characteristics. J Control Release (2010) 0.97
Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats. Pharm Res (2008) 0.95
Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells. Mol Pharm (2008) 0.92
Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates. Biomacromolecules (2012) 0.91
Dendrimeric micelles for controlled drug release and targeted delivery. Mol Pharm (2005) 0.91
Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol Pharm (2008) 0.89
Macromolecular therapeutics. J Control Release (2014) 0.87
Intracellular trafficking and subcellular distribution of a large array of HPMA copolymers. Biomacromolecules (2009) 0.87
Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. J Control Release (2007) 0.87
Nanopharmaceuticals (part 2): products in the pipeline. Int J Nanomedicine (2015) 0.86
Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy. Macromol Biosci (2013) 0.86
Biomaterials and drug delivery: past, present, and future. Mol Pharm (2010) 0.85
Two-step fluorescence screening of CD21-binding peptides with one-bead one-compound library and investigation of binding properties of N-(2-hydroxypropyl)methacrylamide copolymer-peptide conjugates. Biomacromolecules (2006) 0.84
Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines. Biomater Sci (2015) 0.82
Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats. Biomaterials (2013) 0.82
Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates. Macromol Biosci (2012) 0.79
Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment. Int J Pharm (2013) 0.78
The preparation of high conversion polymeric systems containing eugenol residues and their rheological characterization. J Mater Sci Mater Med (2007) 0.77
Design of smart HPMA copolymer-based nanomedicines. J Control Release (2015) 0.76
POLYMERIC BIOMATERIALS AND NANOMEDICINES. J Drug Deliv Sci Technol (2015) 0.76
Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains. Nature (1999) 1.78
Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mater Res (1987) 1.60
Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release (1998) 1.45
Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer (2000) 1.34
HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release (1998) 1.33
Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice. Eur J Cancer (2001) 1.30
Protein-resistant surfaces prepared by PEO-containing block copolymer surfactants. J Biomed Mater Res (1989) 1.24
Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J Control Release (1999) 1.12
Surface properties of copolymers of alkyl methacrylates with methoxy (polyethylene oxide) methacrylates and their application as protein-resistant coatings. Biomaterials (1990) 1.07
Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim Biophys Acta (1986) 1.04
Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. Biochim Biophys Acta (1984) 1.03
Novel pH-sensitive hydrogels with adjustable swelling kinetics. Biomaterials (1998) 1.00
Hybrid hydrogels cross-linked by genetically engineered coiled-coil block proteins. Biomacromolecules (2001) 1.00
Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm Res (1999) 0.99
Long-term experience with poly(glycol monomethacrylate) gel in plastic operations of the nose. J Biomed Mater Res (1975) 0.98
The pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol (1990) 0.98
Polymerizable Fab' antibody fragments for targeting of anticancer drugs. Nat Biotechnol (1999) 0.97
Controlled biodegradability of polymers--a key to drug delivery systems. Biomaterials (1984) 0.97
Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats. Pharm Res (2008) 0.95
Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. Bioconjug Chem (2001) 0.95
Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells. Eur J Cancer (2004) 0.94
HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J Drug Target (1996) 0.94
Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments. Clin Cancer Res (2000) 0.93
Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem Pharmacol (1989) 0.93
Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J Control Release (2001) 0.93
Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e(6)-OV-TL 16 antibody immunoconjugates. J Control Release (2001) 0.93
Photodynamic crosslinking of proteins. II. Photocrosslinking of a model protein-ribonuclease A. J Photochem Photobiol B (1996) 0.92
HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer (1998) 0.92
High-molecular weight HPMA copolymer-adriamycin conjugates. J Control Release (1999) 0.91
Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J Control Release (1999) 0.91
Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers. A potential drug delivery system. Biochim Biophys Acta (1981) 0.91
Polymers containing enzymatically degradable bonds. VI. Hydrophilic gels cleavable by chymotrypsin. Biomaterials (1982) 0.91
Polymers containing enzymatically degradable bonds V. Hydrophilic polymers degradable by papain. Biomaterials (1980) 0.91
A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J Biomater Sci Polym Ed (1994) 0.91
Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. Br J Cancer (1987) 0.90
Photodynamic crosslinking of proteins. III. Kinetics of the FMN- and rose bengal-sensitized photooxidation and intermolecular crosslinking of model tyrosine-containing N-(2-hydroxypropyl)methacrylamide copolymers. Photochem Photobiol (1999) 0.90
Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res (1996) 0.90
Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. Biomaterials (1985) 0.90
Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation. Pharm Res (1992) 0.89
Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues. Biochim Biophys Acta (1983) 0.89
The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors. Pharm Res (2000) 0.88
Prolonged blood circulation in rats of nanospheres surface-modified with semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]. Pharm Res (1995) 0.88
Enantioselective release of 5-fluorouracil from N-(2-hydroxypropyl)methacrylamide-based copolymers via lysosomal enzymes. Bioconjug Chem (1995) 0.87
Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. J Control Release (2007) 0.87
Time- and concentration-dependent apoptosis and necrosis induced by free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J Control Release (2000) 0.86
Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin. J Control Release (2001) 0.86
Chronic exposure of human ovarian carcinoma cells to free or HPMA copolymer-bound mesochlorin e6 does not induce P-glycoprotein-mediated multidrug resistance. Biomaterials (2000) 0.85
Phagocytosis of human blood leukocytes: a simple micromethod. Immunol Lett (1982) 0.85
Photodynamic crosslinking of proteins. I. Model studies using histidine- and lysine-containing N-(2-hydroxypropyl)methacrylamide copolymers. J Photochem Photobiol B (1996) 0.85
Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin Immunol Immunopathol (1988) 0.85
Controlled release of drug model from N-(2-hydroxypropyl)-methacrylamide copolymers. Ann N Y Acad Sci (1985) 0.84
Biorecognition of HPMA copolymer-lectin conjugates as an indicator of differentiation of cell-surface glycoproteins in development, maturation, and diseases of human and rodent gastrointestinal tissues. J Biomed Mater Res (2000) 0.83
The influence of a colonic microbiota on HPMA copolymer lectin conjugates binding in rodent intestine. J Drug Target (2001) 0.83
Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br J Cancer (1988) 0.83
Self-assembled peptides exposing epitopes recognizable by human lymphoma cells. Bioconjug Chem (2000) 0.83
Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials (1984) 0.83
Synthesis of bioadhesive lectin-HPMA copolymer-cyclosporin conjugates. Bioconjug Chem (2000) 0.83
The coiled coils in the design of protein-based constructs: hybrid hydrogels and epitope displays. J Control Release (2001) 0.83
Lysosomal degradability of poly(alpha-amino acids). J Biomed Mater Res (1997) 0.83
Responsive hybrid hydrogels with volume transitions modulated by a titin immunoglobulin module. Bioconjug Chem (2000) 0.83
Immunogenicity of N-(2-hydroxypropyl)-methacrylamide copolymers--potential hapten or drug carriers. Folia Microbiol (Praha) (1983) 0.83
New types of synthetic infusion solutions. III. Elimination and retention of poly-[N-(2-hydroxypropyl)methacrylamide] in a test organism. J Biomed Mater Res (1976) 0.83
Synthesis of starlike N-(2-hydroxypropyl)methacrylamide copolymers: potential drug carriers. Biomacromolecules (2000) 0.83
The cytoplasmic escape and nuclear accumulation of endocytosed and microinjected HPMA copolymers and a basic kinetic study in Hep G2 cells. AAPS PharmSci (2001) 0.82
Cooperativity between free and N-(2-hydroxypropyl) methacrylamide copolymer bound adriamycin and meso-chlorin e6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vitro. Int J Oncol (1999) 0.82
Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci Rep (1982) 0.82
Effect of galactose on interaction of N-(2-hydroxypropyl)methacrylamide copolymers with hepatoma cells in culture: preliminary application to an anticancer agent, daunomycin. Hepatology (1989) 0.82
Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates. J Control Release (2001) 0.82
Macrophages of athymic nude mice: Fc receptors, C receptors, phagocytic and pinocytic activities. Eur J Cell Biol (1984) 0.81
Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs. Int J Pharm (2007) 0.81
Biological tolerance of poly(N-substituted acrylamides). J Biomed Mater Res (1973) 0.81
Effect of porosity of heterogeneous poly(glycol monomethacrylate) gels on the healing-in of test implants. J Biomed Mater Res (1971) 0.81
Release of macromolecules and daunomycin from hydrophilic gels containing enzymatically degradable bonds. J Biomater Sci Polym Ed (1990) 0.81
Potential of lectin-N-(2-hydroxypropyl)methacrylamide copolymer-drug conjugates for the treatment of pre-cancerous conditions. J Control Release (2001) 0.81
Functionalized semitelechelic poly[N-(2-hydroxypropyl)methacrylamide] for protein modification. Bioconjug Chem (1999) 0.81
Modification of cyclosporin A and conjugation of its derivative to HPMA copolymers. Bioconjug Chem (2001) 0.81
Biological tolerance of ionogenic hydrophilic gels. J Biomed Mater Res (1973) 0.80
Co-expression of different types of Fc receptors on murine peritoneal macrophages. Eur J Immunol (1986) 0.80
Improved synthesis and evaluation of 17-substituted aminoalkylgeldanamycin derivatives applicable to drug delivery systems. Bioorg Med Chem Lett (2001) 0.80
Enzymatic degradation and immunogenic properties of derivatized dextrans. Biomaterials (1991) 0.80
Phagocytosis of 2-hydroxyethylmethacrylate copolymer particles by different types of macrophages. Folia Biol (Praha) (1983) 0.80
Biological tolerance of poly(N-substituted methacrylamides). J Biomed Mater Res (1971) 0.80
Evaluation of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug carriers. 1. Binding, pinocytic uptake and intracellular distribution of transferrin and anti-transferrin receptor antibody conjugates. Biochim Biophys Acta (1989) 0.79
New types of synthetic infusion solutions. I. Investigation of the effect of solutions of some hydrophilic polymers on blood. J Biomed Mater Res (1973) 0.79
HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line. Eur J Pharm Biopharm (2000) 0.79
Bioaffinity therapy with antibodies and drugs bound to soluble synthetic polymers. J Chromatogr (1986) 0.79
The effects of subcellular localization of N-(2-hydroxypropyl)methacrylamide copolymer-Mce(6) conjugates in a human ovarian carcinoma. J Control Release (2001) 0.78
Hydrogels for site-specific oral drug delivery: synthesis and characterization. Biomaterials (1991) 0.78
Size-dependent permeability of hydrophilic probes across rabbit colonic epithelium. J Pharmacol Exp Ther (1997) 0.78
Degradation of side chains of N-(2-hydroxypropyl) methacrylamide copolymers by lysosomal enzymes. Biochem Biophys Res Commun (1980) 0.78
Relationship between the structure and biocompatibility of hydrophilic gels. Polim Med (1974) 0.78
Effect of a synthetic poly N-(2-hydroxypropyl)methacrylamide (Duxon) on haemopoiesis and graft-versus-host reaction. Folia Biol (Praha) (1986) 0.78
Influence of pH on aggregation and photoproperties of n-(2-hydroxypropyl)methacrylamide copolymer-meso-chlorin e6 conjugates. Drug Deliv (1998) 0.78
Differences in phagocytic activity of methacrylate copolymer particles in normal and stimulated macrophages. Experientia (1981) 0.78
Biocompatibility of poly (2,4-pentadiene-1-ol). J Biomed Mater Res (1974) 0.78
In vitro degradation of pH-sensitive hydrogels containing aromatic azo bonds. Biomaterials (1997) 0.78
Enzymatic activity of chymotrypsin and its poly(ethylene glycol) conjugates toward low and high molecular weight substrates. Bioconjug Chem (1993) 0.77
Synthesis of N-(2-hydroxypropyl)methacrylamide copolymers with antimicrobial activity. Biomaterials (1983) 0.77
Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes. Pharm Res (1999) 0.77